H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $31 from $32 and keeps a Buy rating on the shares. The firm says the company has “undergone a major transition, pivoting to focus on developing autoimmune therapies from oncology cell therapy.” Vor is currently running two global Phase 3 studies in generalized myasthenia gravis and Sjogren’s disease, the analyst tells investors in a research note. H.C. Wainwright cites dilution for the target trim.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Elbit, Vor, Global-e, Sweetgreen, Immunovant: Insider Shake-Up
- Vor Bio price target raised to $15 from $9 at Wedbush
- Vor Bio price target lowered to $40 from $55 at Stifel
- Vor Biopharma: Solid Clinical Execution and Strengthened Balance Sheet Support Buy Rating and Long-Term Growth Outlook
- Vor Bio doses first patient in UPSTREAM SjD study